Anti-PD-1 monoclonal antibody MEDI0680 in a phase I study of patients with advanced solid malignancies

ALT-803, an IL-15 superagonist, in combination with nivolumab in patients with metastatic non-small cell lung cancer: a non-randomised, open-label, phase 1b trial

(2018) John M Wrangle et al.   LANCET ONCOLOGY

Evaluation of safety and efficacy of p53MVA vaccine combined with pembrolizumab in patients with advanced solid cancers

(2018) V. Chung et al.   Clinical & Translational Oncology

Pembrolizumab monotherapy as first-line therapy in advanced clear cell renal cell carcinoma (accRCC): Results from cohort A of KEYNOTE-427.

(2018) David F. McDermott et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase 1b/2 study of nivolumab in combination with an anti–IL-8 monoclonal antibody, BMS-986253, in a biomarker-enriched population of patients with advanced cancer.

(2018) Ignacio Melero Bermejo et al.   JOURNAL OF CLINICAL ONCOLOGY

Biomarkers for predicting efficacy of PD-1/PD-L1 inhibitors

(2018) Ming Yi et al.   Molecular Cancer

IFN-γ–related mRNA profile predicts clinical response to PD-1 blockade

(2017) Mark Ayers et al.   JOURNAL OF CLINICAL INVESTIGATION

T-cell invigoration to tumour burden ratio associated with anti-PD-1 response

(2017) Alexander C. Huang et al.   NATURE

Tumor Mutational Burden and Response Rate to PD-1 Inhibition

(2017) Mark Yarchoan et al.   NEW ENGLAND JOURNAL OF MEDICINE

Proliferation of PD-1+ CD8 T cells in peripheral blood after PD-1–targeted therapy in lung cancer patients

(2017) Alice O. Kamphorst et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Safety and efficacy profile of pembrolizumab in solid cancer: pooled reanalysis based on randomized controlled trials

(2017) Manni Wang et al.   Drug Design Development and Therapy

Pembrolizumab and nivolumab: PD-1 inhibitors for advanced melanoma

(2016) Igor N. Ivashko et al.   AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY

Immunomodulatory Activity of Nivolumab in Metastatic Renal Cell Carcinoma

(2016) Toni K. Choueiri et al.   CLINICAL CANCER RESEARCH

Development of a programmed cell death ligand-1 immunohistochemical assay validated for analysis of non-small cell lung cancer and head and neck squamous cell carcinoma

(2016) Marlon C. Rebelatto et al.   Diagnostic Pathology

Cancer Treatment with Anti-PD-1/PD-L1 Agents: Is PD-L1 Expression a Biomarker for Patient Selection?

(2016) Lucia Festino et al.   DRUGS

An update on the pharmacodynamics, pharmacokinetics, safety and clinical efficacy of nivolumab in the treatment of solid cancers

(2016) Ashley C. Y. Wong et al.   Expert Opinion on Drug Metabolism & Toxicology

Tumor immune profiling predicts response to anti–PD-1 therapy in human melanoma

(2016) Adil I. Daud et al.   JOURNAL OF CLINICAL INVESTIGATION

Management of Adverse Events Following Treatment With Anti-Programmed Death-1 Agents

(2016) Jeffrey S. Weber et al.   ONCOLOGIST

Analysis of Immune Signatures in Longitudinal Tumor Samples Yields Insight into Biomarkers of Response and Mechanisms of Resistance to Immune Checkpoint Blockade

(2016) P.-L. Chen et al.   Cancer Discovery

PD-1 Blockade Expands Intratumoral Memory T Cells

(2016) A. Ribas et al.   Cancer Immunology Research

Nivolumab in renal cell carcinoma: latest evidence and clinical potential

(2016) Camille Mazza et al.   Therapeutic Advances in Medical Oncology

Intratumoral expression levels of PD-L1, GZMA, and HLA-A along with oligoclonal T cell expansion associate with response to nivolumab in metastatic melanoma

(2016) Hiroyuki Inoue et al.   OncoImmunology

Immune Checkpoint Blockade: A Common Denominator Approach to Cancer Therapy

(2015) Suzanne L. Topalian et al.   CANCER CELL

Phase I Study of Pembrolizumab (MK-3475; Anti-PD-1 Monoclonal Antibody) in Patients with Advanced Solid Tumors

(2015) A. Patnaik et al.   CLINICAL CANCER RESEARCH

Nivolumab: targeting PD-1 to bolster antitumor immunity

(2015) Julie R Brahmer et al.   Future Oncology

The S228P Mutation Preventsin Vivoandin VitroIgG4 Fab-arm Exchange as Demonstrated using a Combination of Novel Quantitative Immunoassays and Physiological Matrix Preparation

(2015) John-Paul Silva et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Nivolumab for Metastatic Renal Cell Carcinoma: Results of a Randomized Phase II Trial

(2015) Robert J. Motzer et al.   JOURNAL OF CLINICAL ONCOLOGY

Nivolumab in Previously Untreated Melanoma without BRAF Mutation

(2015) Caroline Robert et al.   NEW ENGLAND JOURNAL OF MEDICINE

Association of PD-1, PD-1 Ligands, and Other Features of the Tumor Immune Microenvironment with Response to Anti-PD-1 Therapy

(2014) J. M. Taube et al.   CLINICAL CANCER RESEARCH

Survival, Durable Tumor Remission, and Long-Term Safety in Patients With Advanced Melanoma Receiving Nivolumab

(2014) Suzanne L. Topalian et al.   JOURNAL OF CLINICAL ONCOLOGY

Combination Therapy with Anti–CTLA-4 and Anti–PD-1 Leads to Distinct Immunologic Changes In Vivo

(2014) Rituparna Das et al.   JOURNAL OF IMMUNOLOGY

Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial

(2014) Caroline Robert et al.   LANCET

PD-1 blockade induces responses by inhibiting adaptive immune resistance

(2014) Paul C. Tumeh et al.   NATURE

Novel immune checkpoint blocker approved for the treatment of advanced melanoma

(2014) Lorenzo Galluzzi et al.   OncoImmunology

Mutational heterogeneity in cancer and the search for new cancer-associated genes

(2013) Michael S. Lawrence et al.   NATURE

Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma

(2013) Omid Hamid et al.   NEW ENGLAND JOURNAL OF MEDICINE

Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer

(2012) Suzanne L. Topalian et al.   NEW ENGLAND JOURNAL OF MEDICINE

One target, different effects: a comparison of distinct therapeutic antibodies against the same targets

(2011) Hyunbo Shim   EXPERIMENTAL AND MOLECULAR MEDICINE

The Programmed Death-1 Ligand 1:B7-1 Pathway Restrains Diabetogenic Effector T Cells In Vivo

(2011) A. M. Paterson et al.   JOURNAL OF IMMUNOLOGY

B7-H1/CD80 interaction is required for the induction and maintenance of peripheral T-cell tolerance

(2010) J.-J. Park et al.   BLOOD

Immunogenicity of Anti-TNF-α Agents in Autoimmune Diseases

(2009) Nádia Emi Aikawa et al.   CLINICAL REVIEWS IN ALLERGY & IMMUNOLOGY

Antibody tumor penetration: Transport opposed by systemic and antigen-mediated clearance

(2008) Greg M. Thurber et al.   ADVANCED DRUG DELIVERY REVIEWS